KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Preferred Shares: 2017

  • Aquestive Therapeutics' Preferred Shares was N/A to $21.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $21.9 million, marking a year-over-year change of. This contributed to the annual value of $21.9 million for FY2017, which is N/A change from last year.
  • Latest data reveals that Aquestive Therapeutics reported Preferred Shares of $21.9 million as of Q4 2017.
  • Over the past 5 years, Aquestive Therapeutics' Preferred Shares peaked at $21.9 million during Q4 2017, and registered a low of $21.9 million during Q4 2017.
  • Its 1-year average for Preferred Shares is $21.9 million, with a median of $21.9 million in 2017.